ADCC/ADCP-Enhanced Antibody Expression Vectors

Fc-engineered human IgG1 expression vectors featuring DE, DLE, ADE, GASDALIE, and G236A mutations for investigating enhanced Fc receptor interactions, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP).

ADCC/ADCP-ENHANCED ANTIBODY EXPRESSION VECTOR SELECTION GUIDE

Compare five Fc-engineered human IgG1 expression vectors to select an appropriate variant for your antibody engineering research.

Catalog No. Variant Engineering Mechanism Selection Guidance
AFV-01 Human IgG1 (DE) S239D / I332E Two-residue Fc engineering for enhanced Fcγ receptor engagement.
AFV-02 Human IgG1 (DLE) S239D / A330L / I332E Three-residue Fc engineering for ADCC-focused studies.
AFV-17 Human IgG1 (GASDALIE) G236A / S239D / A330L / I332E Four-residue Fc engineering for ADCC/ADCP research and Fcγ receptor interaction studies.
AFV-18 Human IgG1 (ADE) G236A / S239D / I332E Combined Fc engineering for ADCC/ADCP studies.
AFV-19 Human IgG1 (G236A) G236A Single-residue variant for investigating FcγRIIa-related interactions and phagocytosis.

Functional enhancement depends on antibody sequence, Fc receptor subtype and polymorphism, target cells, and assay conditions. Confirm Fcγ receptor binding and ADCC/ADCP activity experimentally.

Showing all 5 results